Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-323 DDI Study with Itraconazole, Carbamazepine, Quinidine, and Fluconazole
NCT06847464Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EDP-323 in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 13 and Area Under the Curve at Day 13. Started Jan 2025; status: completed.
02
Drugs
EDP-323
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06847464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847464.